

## H. Lundbeck A/S

Ottiliavej 9  
DK-2500 Valby, Copenhagen

Tel +45 36 30 13 11  
Fax +45 36 43 82 62

E-mail [investor@lundbeck.com](mailto:investor@lundbeck.com)  
[www.lundbeck.com](http://www.lundbeck.com)



Corporate Release No 401

16 April 2010

### **Update on legal proceedings**

H. Lundbeck A/S (Lundbeck) has been informed of a favorable ruling from the City Court in Elsinore in a preliminary injunction case in Denmark. The decision means that generic versions of escitalopram in Denmark have to be removed from the market. The decision can be appealed by the other side.

At the same time Lundbeck has received the outcome of a preliminary injunction case, held before the Commercial Court of Barcelona, regarding infringement of the escitalopram patent in Spain.

The court decided to lift the ex parte injunction made against companies preparing to market a generic version of escitalopram in Spain. Lundbeck does not agree with the court ruling and will appeal the decision.

As a result of the ruling Lundbeck expects generic versions of escitalopram to be available in Spain within a short period of time. The entrance of generic versions into the market is expected to have a moderate impact on Cipralex<sup>®</sup> sales on the Spanish market in 2010.

A prerequisite for Lundbeck's continued investments in innovative pharmaceuticals is that intellectual property rights are respected. As the Lundbeck Group's intellectual property rights are valid and hence enforceable, it is Lundbeck's policy to enforce its intellectual property rights, wherever they may be violated.

### **Financial guidance**

The content of this release will have no influence on the Lundbeck Group's financial guidance for 2010.



## **Lundbeck contacts**

### *Investors:*

Jacob Tolstrup  
Vice President, IR & Communication  
+45 36 43 30 79

Palle Holm Olesen  
Chief Specialist; Investor Relations  
+45 36 43 24 26

Magnus Thorstholm Jensen  
Investor Relations Officer  
+45 36 43 38 16

### *Media:*

Mads Kronborg  
Media Relations Manager  
+45 36 43 28 51

Stine Hove Marsling  
External Communication Specialist  
+45 36 43 28 33

## **About Lundbeck**

H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improve the quality of life for people suffering from central nervous system (CNS) disorders. For this purpose Lundbeck is engaged in the research and development, production, marketing and sale of pharmaceuticals across the world, targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington's, Alzheimer's and Parkinson's diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark, and employs today approximately 5,900 people worldwide. Lundbeck is one of the world's leading pharmaceutical companies working with CNS disorders. In 2009, the company's revenue was DKK 13.7 billion (approximately EUR 1.8 billion or USD 2.6 billion). For more information, please visit [www.lundbeck.com](http://www.lundbeck.com).